Enstilar (Calcipotriene/Betamethasone) Patent Expiration, LOE Window & CMS Spending

Enstilar (Calcipotriene/Betamethasone) by Leo As: FDA Orange Book LOE 2031-12-10, 3 AB generics, $9.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLeo As
FDA Application & PathwayN207589 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-12-10
Orange Book Patents (*PED Extensions)10 patents (2 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$9.6M
2024 Medicare Part D Spend$6.9M
2024 Medicaid Spend$2.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel